ProCE Banner Activity

Retreatment With Radium-223 Safe, Showing Activity in Patients With CRPC and Bone Metastases

Slideset Download
Conference Coverage
Results from this small exploratory study suggest that radium-223 retreatment is well tolerated and may help delay future bone events in patients with CRPC and bone metastases who experience radiographic or clinical progression following an initial course of radium-223.

Released: June 07, 2016

Expiration: June 06, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals